Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
polymyxin B-sulfat, præparation til oftalmisk anvendelse |
Is a |
False |
Polymyxin B (substance) |
Inferred relationship |
Some |
|
Polymyxin B sulfate |
Is a |
False |
Polymyxin B (substance) |
Inferred relationship |
Some |
|
polymyxin B sulfat-præparat til anvendelse i øre |
Is a |
False |
Polymyxin B (substance) |
Inferred relationship |
Some |
|
Sulfomyxin |
Is a |
False |
Polymyxin B (substance) |
Inferred relationship |
Some |
|
Polymixin-B measurement |
Component |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
1 |
Polymyxin B adverse reaction (disorder) |
Causative agent |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
1 |
Allergy to polymyxin B |
Causative agent |
False |
Polymyxin B (substance) |
Inferred relationship |
Some |
|
polymyxin B-øjensalve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B (substance) |
Inferred relationship |
Some |
|
øjendråber indeholdende polymyxin B |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B (substance) |
Inferred relationship |
Some |
|
polymyxin B-sulfat + trimethoprim øjendråber |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B (substance) |
Inferred relationship |
Some |
|
polymyxin B-sulfat + bacitracinzink øjensalve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B (substance) |
Inferred relationship |
Some |
|
polymyxin B-sulfat + trimethoprim øjensalve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B (substance) |
Inferred relationship |
Some |
|
polymyxin B-sulfat + bacitracinzink 10.000 enheder/500 enheder øjensalve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B (substance) |
Inferred relationship |
Some |
|
dexamethason 0,1 % wt/vol + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder salve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B (substance) |
Inferred relationship |
Some |
|
dexamethason 0,1 % wt/vol + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B (substance) |
Inferred relationship |
Some |
|
gramicidin 0,025 mg + neomycinsulfat 1,75 mg + polymyxin B-sulfat 10.000 enheder opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B (substance) |
Inferred relationship |
Some |
|
hydrocortison + neomycinsulfat + polymyxin B-sulfat 10 mg/5 mg/1,6 mg suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B (substance) |
Inferred relationship |
Some |
|
hydrocortison 10 mg + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B (substance) |
Inferred relationship |
Some |
|
hydrocortison + neomycinsulfat + polymyxin B-sulfat 10 mg/7,5 mg/10.000 enheder suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B (substance) |
Inferred relationship |
Some |
|
hydrocortison 10 mg + neomycinsulfat 7,5 mg + polymyxin B-sulfat 1.000 enheder opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B (substance) |
Inferred relationship |
Some |
|
hydrocortison + polymyxin B 5 mg/10.000 enheder dråber |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B (substance) |
Inferred relationship |
Some |
|
hydrocortisonacetat 5 mg + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder creme |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B (substance) |
Inferred relationship |
Some |
|
neomycinsulfat + polymyxin B-sulfat + prednisolonacetat 0,35 %/10.000 enheder/0,5 % wt/vol suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B (substance) |
Inferred relationship |
Some |
|
polymyxin B-sulfat + trimethoprimsulfat 10.000 enheder/1 mg opløsning til oftalmisk anvendelse |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B (substance) |
Inferred relationship |
Some |
|
Product containing polymyxin B (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
1 |
Product containing lidocaine and neomycin and polymyxin B (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
1 |
Product containing neomycin and polymyxin B and pramocaine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
1 |
Product containing bacitracin and neomycin and polymyxin B and pramocaine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
1 |
Product containing neomycin and polymyxin B (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
1 |
Product containing polymyxin B and trimethoprim (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
1 |
Product containing bacitracin and polymyxin B (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
1 |
Product containing polymyxin B in ophthalmic dosage form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B (substance) |
Inferred relationship |
Some |
|
Product containing polymyxin B in parenteral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
1 |
Product containing polymyxin B in topical dosage form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B (substance) |
Inferred relationship |
Some |
|
Polymyxin B-containing product in otic dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
1 |
Product containing polymyxin B in vaginal dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
1 |
Allergy to polymyxin B |
Causative agent |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
1 |
Polymyxin B sulfate |
This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
|
Product containing neomycin and polymyxin B and prednisolone (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
2 |
Product containing dexamethasone and neomycin and polymyxin B (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
2 |
Product containing bacitracin and neomycin and polymyxin B (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
1 |
Product containing bacitracin and hydrocortisone and neomycin and polymyxin B (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
1 |
Product containing hydrocortisone and neomycin and polymyxin B (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
1 |
Product containing polymyxin B in ocular dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
1 |
Product containing polymyxin B in cutaneous dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
1 |
Bacitracin and neomycin and polymyxin B only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
1 |
Product containing only bacitracin and neomycin and polymyxin B and pramocaine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
1 |
Product containing only bacitracin and polymyxin B (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
1 |
Product containing only bacitracin and hydrocortisone and neomycin and polymyxin B (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
1 |
Dexamethasone and neomycin and polymyxin B only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
2 |
Neomycin and polymyxin B and pramocaine only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
1 |
Neomycin and polymyxin B and prednisolone only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
2 |
Hydrocortisone and neomycin and polymyxin B only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
1 |
Product containing only neomycin and polymyxin B (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
1 |
Lidocaine and neomycin and polymyxin B only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
1 |
Product containing only polymyxin B (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
1 |
Product containing only polymyxin B and trimethoprim (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
1 |
Polymyxin B only product in cutaneous dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
1 |
Polymyxin B only product in ocular dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
1 |
Polymyxin B only product in otic dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
1 |
Product containing only polymyxin B in parenteral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
1 |
Product containing only polymyxin B in vaginal dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
1 |
Polymyxin B (as polymyxin B sulfate) 500000 unit powder for solution for injection vial |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
1 |
Product containing only dexamethasone and neomycin and polymyxin B in ocular dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely dexamethasone 1 milligram/1 milliliter and neomycin (as neomycin sulfate) 3500 unit/1 milliliter and polymyxin B sulfate 6000 unit/1 milliliter conventional release suspension for eye drops (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely dexamethasone 1 milligram/1 milliliter and neomycin (as neomycin sulfate) 3500 unit/1 milliliter and polymyxin B sulfate 6000 unit/1 milliliter conventional release suspension for eye drops (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
2 |
Product containing dexamethasone and neomycin and polymyxin B in ocular dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Polymyxin B (substance) |
Inferred relationship |
Some |
2 |